Location of Repository

ΧΗΜΕΙΟΠΡΟΦΥΛΑΞΗ ΤΩΝ ΕΠΙΦΑΝΕΙΑΚΩΝ ΟΓΚΩΝ ΤΗΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ ΜΕ ΕΝΔΟΚΥΣΤΙΚΕΣ ΕΓΧΥΣΕΙΣ 4-EPI-DOXORUBICIN

By ΧΟΥΣΑΜ ΔΑΟΥΑΧΕΡ

Abstract

A CONTROLLED PROSPECTIVE STUDY IN 99 PATIENTS WAS DONE TO EVALUATE THE EFFICACYOF INTRAVESICAL EPIRUBICIN ADMINISTRATION AS PROPHYLACTIC TREATMENT IN REGARD TO THE PATTERN OF TUMOR RECURRENCES AFTER COMPLETE ENDOSCOPIC RESECTION OF SUPERFICIAL TRANSITIONAL CELL CARCINOMA OF THE BLADDER (STAGE TA, T1). INTRAVESICAL INSTILLATIONS OF 50 MG EPIRUBICIN WERE GIVEN WEEKLY FOR 6 CONSECUTIVE WEEKS AND TO THE RESPONDERS AN INTERMITTENT MAINTENANCE THERAPY WAS ADMINISTERED FOR THE FIRST 2 YEARS AFTER EACH FOLLOW-UP EXAMINATION. OF THE PATIENTS 67 WERE TREATED PROPHYLACTICALLY WITH EPIRUBICIN (GROUP A) 40% HAD RECURRENCE WITHIN A TOTAL OF 1,307 MONTHS COMPARED TO 32 PATIENTS OF THE CONTROLS (GROUP B) WHO WERE FOLLOWED CONVENTIONALLY 59% HAD RECURRENCE WITHIN A TOTAL OF 393 MONTHS, A DIFFERENCE THAT WAS NOT STATISTICALLY SIGNIFICANT (P > 0,05). HOWEVER, EXAMINING THE RESULTS IN ANOTHER MANNER, THE CONTROL PATIENTS DEMONSTRATED A SIGNIFICANTLY SHORTER MEAN INTERVAL TO RECURRENCE 16,2 AND 11,05 MONTHS FOR GROUP A AND B RESPECTIVELY AND HIGHER RECCURENT TUMOR RATE PER 100 PATIENT-MOUNTS (1,55 FOR GROUP A AND 3,15 FOR GROUP B). TO CLARIFY FURTHER THE EFFICACY OF EPIRUBICIN THERAPY, COMPARISONS OF THE TREATMENT OUTCOME ACCORDING TO SEVERAL TUMOR FACTORS WERE DONE. THESE COMPARISONS REVEALED A SIGNIFICANT BENEFIT FOR THOSE WHO RECEIVED EPIRUBICIN WITH RESPECT TO HISTORY OF TUMOR RECURRENCES AND MULTIPLICITY AT PRESENTATION. (ABSTRACT TRUNCATED)

Topics: Bladder, EPIRUBICIN, INTRAVISICAL INSTILLATION, Prophylaxis, SUPERFICIAL TUMORS, ΕΝΔΟΚΥΣΤΙΚΗ ΕΓΧΥΣΗ, ΕΠΙΦΑΝΕΙΑΚΑ ΝΕΟΠΛΑΣΜΑΤΑ ΚΥΣΤΗΣ, Προφύλαξη
Publisher: University of Patras
Year: 1994
DOI identifier: 10.12681/eadd/3299
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://hdl.handle.net/10442/he... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.